Ignite Creation Date:
2024-05-06 @ 2:16 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04265534
Status:
TERMINATED
Last Update Posted:
2022-09-21
First Post:
2020-02-07
Brief Title:
KEAPSAKE A Study of Telaglenastat CB-839 With Standard-of-Care Chemoimmunotherapy in 1L KEAP1NRF2-Mutated Nonsquamous NSCLC
Sponsor:
Calithera Biosciences Inc
Organization:
Calithera Biosciences Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| NFE2L2 Gene Mutation |
| Non-Small Cell Lung Cancer |
| Non-squamous Non-small-cell Lung Cancer |
| Non-Squamous Non-Small Cell Neoplasm of Lung |
| KEAP1 Gene Mutation |
| NRF2 Gene Mutation |
Keywords:
| Name | View |
|---|---|
| Guardant360 | View |
| NSCLC | View |
| KEAP1 | View |
| NRF2 | View |
| NFE2l2 | View |
| LKB1 | View |
| STK11 | View |
| Next Generation Sequencing | View |
| NGS | View |
| Mutation | View |
| Pembrolizumab | View |
| Pemetrexed | View |
| Carboplatin | View |
| Randomized | View |
| Placebo | View |
| Chemotherapy | View |
| Targeted Therapy | View |
| Telaglenastat | View |
| Glutamine | View |
| Glutaminase | View |
| Glutathione | View |
| Immunotherapy | View |
| Front-line | View |
| First-line | View |
| Non-squamous | View |
| Keytruda | View |
| Alimta | View |